Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 18, Number 1—January 2012

CME ACTIVITY - Research

Accelerating Control of Pertussis in England and Wales

Helen CampbellComments to Author , Gayatri Amirthalingam, Nick Andrews, Norman K. Fry, Robert C. George, Timothy G. Harrison, and Elizabeth Miller
Author affiliations: Health Protection Agency, London, UK

Main Article

Table 4

Estimated effectiveness of a 3-dose pertussis vaccine schedule among case-patients with culture- or PCR-confirmed pertussis, by vaccine cohort and age group, England, 1998–2009*

Vaccine cohort† Age group of pertussis case-patients
12–39 mo
40–59 mo
5–9 y
10–16 y
No. vaccinated/ no. total % VE
(95% CI) No. vaccinated/ no. total % VE
(95% CI) No. vaccinated/ no. total % VE
(95% CI) No. vaccinated/ no. total % VE
(95% CI)
1 5/8 92
(48.8–98.5) 15/26 87.2
(69.2–94.5)
2 25/52 97.7
(95.9–98.7) 38/57 95.7‡
(92.2–97.6) 94/125 92.8‡
(88.8–95.2) 39/44 82.0‡
(41.4–92.9)
3 12/37 98.7
(97.4–99.4) 2/5 98.4§
(85.9–99.9) 1/4 99.2§
(89.9–100.0)
4 8/21 98.4
(95.9–99.4) 1/2 0/1
5 11/19 96.6
(90.2–98.7)
Overall total 56/129 98.1
(97.2–98.7) 41/64 96.1
(93.3–97.7) 100/138 93.4
(90.1–95.5) 54/70 83.7
(69.5–90.8)

*VE, vaccine effectiveness; –, no cases that met the criteria were identified during 1998–2009 and, therefore, VE could not be calculated, or case nos. were too small for calculation purposes.
†Vaccine cohorts: cohort 1, received diphtheria/tetanus/whole-cell pertussis vaccine (DTwP) at 3, 5, and 11 mo of age; cohort 2, received DTwP at 2, 3, and 4 mo of age; cohort 3, received DTwP or DTaP3 (DT/3-component acellular pertussis vaccine) at 2, 3, and 4 mo of age; cohort 4, received DTwP at 2, 3, 4 mo of age; cohort 5, received DTaP5 at 2, 3, and 4 mo of age.
‡VE mainly reflects 3 doses; however, some eligible children had received 4 doses.
§Some children were eligible for a booster vaccination; thus, VE is for 3 or 4 doses.

Main Article

TOP